Source – Fierce Pharma
A competitor medication from Takeda is currently in low supply after a lengthy scarcity of the attention-deficit hyperactivity disorder (ADHD) treatment Adderall and its generics in the United States.
Takeda claimed it is “currently experiencing low inventory” of the ADHD medication due to a “manufacturing delay compounded by increased demand” in a statement on the Vyvanse patient website.
It has become more difficult for the business to “provide adequate supply to pharmaceutical distribution wholesalers who, in turn, supply retail pharmacies” like Walgreens, Rite Aid, and CVS.
According to Takeda, the circumstance has an impact on the 40-mg, 60-mg, and 70-mg dose strengths of Vyvanse. In mid-June, the supply of 40-mg doses “will dip and will be replenished in a few weeks,” according to a statement from Takeda.
Supply shortfalls for the two higher doses are expected to begin in “late June or early July and continue into September,” Takeda said.
“We regret this inconvenience and potential disruption in your treatment,” the company said in its statement.
The lack of Vyvanse comes after several months of Adderall and its generic counterparts being out of stock. When Teva, the major supplier to the United States, began to struggle to meet demand, the shortage began in August of last year.
When ADHD diagnoses increase, Teva encounters a supply problem with Adderall and promises quick refilling. As other businesses started experiencing their own shortages over the course of the following several months, Teva stated that their scarcity will last for quite some time.
According to the shortage database maintained by the American Society of Health-System Pharmacists, at least eight businesses are now experiencing Adderall shortages. In October, the FDA made public the countrywide Adderall shortage.
